Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Cyamemazine

Introduction

Overview

Overview

Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class which was introduced by Theraplix in France in 1972 and later in Portugal as well.[1][2][3][4] It is used for the treatment of schizophrenia and, especially, for psychosis-associated anxiety, due to its unique anxiolytic efficacy.[5][6]

Cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of dopamine, α1-adrenergic, H1, and mACh receptor antagonism,[7] it additionally produces potent blockade of several serotonin receptors, including 5-HT2A, 5-HT2C, and 5-HT7.[7][8][9][10] These actions have been implicated in cyamemazine’s anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A),[7][8] and despite being classified as a typical, it actually behaves like an atypical antipsychotic.[11]

See also

See also

References

References

  1. ↑ Index nominum, international drug … – Google Books.
  2. ↑ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 534. ISBN 0-412-46630-9.
  3. ↑ Pharmaceutical manufacturing … – Google Books.
  4. ↑ Bret P, Bret MC, Queuille E (April 2009). “[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]”. L’Encéphale (in French). 35 (2): 129–38. doi:10.1016/j.encep.2008.03.007. PMID 19393381.
  5. ↑ “Stahl’s Essential Psychopharmacology – Cambridge University Press”.
  6. ↑ Bourin M, Nic Dhonnchadha BA, Claude Colombel M, Dib M, Hascoët M (September 2001). “Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice”. Behavioural Brain Research. 124 (1): 87–95. doi:10.1016/S0166-4328(01)00238-8. PMID 11423169.
  7. ↑ 7.0 7.1 7.2 Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). “Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes”. Biochemical Pharmacology. 65 (3): 435–40. doi:10.1016/S0006-2952(02)01515-0. PMID 12527336.
  8. ↑ 8.0 8.1 Alvarez-Guerra M, d’Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). “5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity”. Psychopharmacology. 147 (4): 412–7. doi:10.1007/s002130050010. PMID 10672635.
  9. ↑ Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP (November 2002). “5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle”. European Journal of Pharmacology. 454 (2–3): 235–9. doi:10.1016/S0014-2999(02)02489-5. PMID 12421652.
  10. ↑ Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A (January 2008). “Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes”. European Journal of Pharmacology. 578 (2–3): 142–7. doi:10.1016/j.ejphar.2007.09.025. PMID 17936750.
  11. ↑ Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M (February 2003). “Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine”. Naunyn-Schmiedeberg’s Archives of Pharmacology. 367 (2): 134–9. doi:10.1007/s00210-002-0665-4. PMID 12595954.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]